Patent 9221891 was granted and assigned to Moderna Therapeutics on December, 2015 by the United States Patent and Trademark Office.
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.